Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Characteristics of a Chronic Pain Phenotype in Adults with Sickle Cell Disease
source: American Society of Hematology
year: 2017
authors: James G. Taylor, Kathleen Vaughan, Lena Diaw, Caterina Minniti, Inna Belfer
summary/abstract:Sickle cell disease (SCD) is characterized by pain, typically, acute in onset with a subset of events which require hospitalization for treatment with opioid analgesics. A proportion of adults also experience nearly daily pain that appears to share features with chronic pain in other diseases. However, the prevalence of chronic SCD pain in adults is largely undefined. Furthermore, the relationship between chronic pain in SCD and mortality has not been evaluated despite the known association between frequent acute pain crises and increased risk of death. The American Pain Society Pain Taxonomy working group on SCD has recently proposed core diagnostic criteria for chronic pain, although these criteria were not based upon population based data.
Results: Forty-nine (21%) met the chronic pain definition. Mean age was 31.1 versus 32.1 years, respectively, and there was no sex difference between groups. Characteristics distinguishing the chronic pain group from all others were a higher body mass index (BMI; P=0.007), more hospitalizations for SCD pain over the past year (mean 6.6 hospitalizations for the chronic pain group; P< 0.0001), a higher number of moderate pain days (i.e. missing work; mean of 66.3 days; P< 0.0001), avascular necrosis in 49% of chronic pain patients (odds ratio 2.53 compared to all others; 95% confidence interval 1.33 to 4.85; P=0.006) and a higher prevalence of any current opioid use (90% versus 69%, P=0.003). In men, priapism was more prevalent for those with chronic pain (71% versus 46% respectively; odds ratio 2.80; 95% confidence interval 1.07 to 7.34; P=0.04). Systolic and diastolic blood pressure were also higher with chronic pain, but these were not quite statistically significant (P=0.06 for both). Overall, the proportion of subjects with both chronic pain and any contributory disease complications defined by the Pain Taxonomy working group (like leg ulcers or avascular necrosis) was 57% (28 out of 49), even though leg ulcers by themselves were not associated with chronic pain (P=0.52). Direct bilirubin was also higher and approached significance (P=0.053), but no other lab studies were associated with chronic pain. Multivariable logistic regressions showed that the number of hospitalizations for pain during the 12 months prior to evaluation (P=2.14 x 10-6), current opioid use (P=0.02) and higher systolic blood pressure (P=0.007) were independent markers associated with chronic pain. Finally, the chronic pain group was not at increased risk of death (Hazard Ratio 1.26; 95% CI 0.24 – 6.63; P=0.79) in a Kaplan Meier survival analysis with a median follow-up of 1.4 years for 174 subjects.
organization: Howard University College of Medicine, Washington, DC; National Institutes of Health, Bethesda, MD; Albert Einstein College of Medicine, Bronx, NYread more
+myBinderRelated Content
-
The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by AssociationIn 2008, for the first time in Centers f...
-
Albuminuria, serum antioxidant enzyme levels and markers of hemolysis and inflammation in steady state children with...BACKGROUND: Oxidative stress is thought ...
-
SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain CrisesResults from the Phase 2 SUSTAIN clinica...
-
The Indiana Hemophilia & Thrombosis CenterThe Indiana Hemophilia & Thrombosis ...
-
Reproductive Issues for Women With Sickle Cell Diseasehttps://www.youtube.com/watch?v=4vo_BPBn...
-
A multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
-
Hydroxyurea Treatment in Men with SCA Leads to Drop in Total Sperm Count, Study ShowsResearchers found that treatment with hy...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.